|
KMID : 0360220090500091359
|
|
Journal of the Korean Ophthalmological Society
2009 Volume.50 No. 9 p.1359 ~ p.1370
|
|
|
Therapeutic Effects of Intravitreal Bevacizumab Injection for Retinal Neovascularization Secondary to Proliferative Diabetic Retinopathy
|
|
Chang June-Kyu
Chang Moo-Hwan
|
|
|
Abstract
|
|
|
Purpose: To evaluate the short-term effects of a single intravitreal injection of bevacizumab (Avastin) for the management of new vessels (NV) associated with proliferative diabetic retinopathy (PDR).
Methods: A non-randomized study of 19 PDR patients (20 eyes) who had active NV was analyzed prospectively. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 4, and 8 after intravitreal injection of 1.25 mg of bevacizumab. The main outcome measures included changes in total area of fluorescein leakage from active NV and best corrected visual acuity (BCVA).
Results: Twenty eyes of 19 patients (12 men [63.2%], 7 women [36.8%]) were included and all patients completed the 8-week study follow-up period. The mean age of participants was 47.05±12.48 years. At baseline, NV area was 23.02±21.80 mm2. The area of active NV decreased significantly to 4.96±9.18 mm2, 1.11±4.96 mm2 and 4.55±5.11 mm2 (p<0.05) at 1, 4 and 8 weeks after injection, respectively. At week 4, no leakage was observed in 19 eyes. The mean logMAR BCVA improved from 0.59±0.49 at baseline to 0.56±0.47, 0.55±0.73 and 0.51±0.50 at weeks 1, 4, and 8, respectively. No significant adverse events were observed.
Conclusions: Short-term results suggest that intravitreal injection of bevacizumab is associated with a rapid regression of retinal neovascularization secondary to PDR.
|
|
|
KEYWORD
|
|
|
Intravitreal Bevacizumab, Proliferative diabetic retinopathy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|